CRISPR Therapeutics AG
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
11.17 |
41.40 |
113.13 |
189.73 |
226.95 |
352.55 |
| Przychód Δ r/r |
0.00% |
270.74% |
173.29% |
67.70% |
19.62% |
55.34% |
| Przychód (min) |
1.24 |
1.02 |
2.80 |
4.70 |
5.62 |
8.73 |
| Przychód (max) |
36.81 |
168.96 |
461.75 |
774.36 |
926.28 |
1,438.90 |
| EBITDA (średnia) |
-6.96 |
-25.81 |
-70.54 |
-118.29 |
-141.50 |
-219.80 |
| EBIT (średnia) |
-7.12 |
-26.42 |
-72.19 |
-121.06 |
-144.81 |
-224.96 |
| EBIT % |
-63.81% |
-63.81% |
-63.81% |
-63.81% |
-63.81% |
-63.81% |
| Zysk netto (średni) |
-475.66 |
-462.75 |
-392.49 |
-275.08 |
-193.70 |
271.40 |
| Zysk netto % |
-4259.81% |
-1117.81% |
-346.92% |
-144.98% |
-85.35% |
76.98% |
| EPS (średnia) |
-5.16 |
-5.49 |
-4.52 |
-3.66 |
-2.30 |
3.22 |
| Liczba analityków (Przychody) |
21 |
17 |
24 |
13 |
8 |
12 |
| Liczba analityków (EPS) |
20 |
19 |
22 |
9 |
4 |
3 |
| symbol |
CRSP |
CRSP |
CRSP |
CRSP |
CRSP |
CRSP |